Cannabidiol (Swedish Wikipedia)

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (August 2007). "Cannabidiol—recent advances". Chem. Biodivers. (Review). 4 (8): 1678–92. doi:10.1002/cbdv.200790147. PMID 17712814.
Pertwee RG (2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin". British Journal of Pharmacology. 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007). "The orphan receptor GPR55 is a novel cannabinoid receptor". British Journal of Pharmacology. 152 (7): 1092–101. doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR (January 2010). "Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors". British Journal of Pharmacology. 159 (1): 122–8. doi:10.1111/j.1476-5381.2009.00521.x. PMC 2823358. PMID 20002102.
Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS (January 2009). "5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats". British Journal of Pharmacology. 156 (1): 181–8. doi:10.1111/j.1476-5381.2008.00046.x. PMC 2697769. PMID 19133999.
Campos AC, Guimarães FS (August 2008). "Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats". Psychopharmacology. 199 (2): 223–30. doi:10.1007/s00213-008-1168-x. PMID 18446323.
Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M (May 2005). "Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism". Stroke; a Journal of Cerebral Circulation. 36 (5): 1077–82. doi:10.1161/01.STR.0000163083.59201.34. PMID 15845890
Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). "Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance". Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118
Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (2006). "Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 372 (5): 354–361. doi:10.1007/s00210-006-0033-x. PMID 16489449

dx.doi.org

McPartland JM, Russo EB (2001). ”Arkiverade kopian” (på engelska). Journal of Cannabis Therapeutics 1 (3/4): sid. 103–132. doi:10.1300/J175v01n03_08. Arkiverad från originalet den 22 juni 2017. https://web.archive.org/web/20170622203721/http://www.cannabis-med.org/data/pdf/2001-03-04-7.pdf. Läst 8 juli 2015.
Borgelt LM, Franson KL, Nussbaum AM, Wang GS (februari 2013). ”The pharmacologic and clinical effects of medical cannabis” (på engelska). Pharmacotherapy 33 (2): sid. 195–209. doi:10.1002/phar.1187. PMID 23386598.
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (december 2012). ”Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders” (på engelska). Philosophical Transactions of the Royal Society B: Biological Sciences 367 (1607): sid. 3364–3378. doi:10.1098/rstb.2011.0389. PMID 23108553.

domstol.se

”CBD-olja som innehåller THC bedöms vara narkotika”. Sveriges Domstolar. 18 juni 2019. https://www.domstol.se/nyheter/2019/06/cbd-olja-som-innehaller-thc-bedoms-vara-narkotika/. Läst 6 april 2021.

europa.eu

ema.europa.eu

”Epidyolex”. ema.europa.eu. https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex. Läst 31 mars 2022.

fda.gov

”FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy”. fda.gov. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms. Läst 31 mars 2022.

formulaswiss.com

se.formulaswiss.com

Alastair Good (26 oktober 2010). ”Growing marijuana that won't get you high” (på engelska). The Daily Telegraph, London. Arkiverad från originalet den 28 januari 2016. https://web.archive.org/web/20160128082457/http://se.formulaswiss.com/. Läst 8 juli 2015.

greenbudguru.com

”History of cannabis and its Derivatives (Explained)”. greenbudguru.com. https://www.greenbudguru.com/history-of-cannabis. Läst 31 mars 2022.

hempembassy.it

”Referendum Cannabis legale: ottenute 500 mila firme”. hempembassy.it. 2021-09-24. https://hempembassy.it/referendum-cannabis-legale-ottenute-500-mila-firme-cosa-succedera/.

lakemedelsverket.se

”CBD products should follow the drug laws”. CBD products should follow the drug laws. Swedish Medical Products Agency. April 4, 2018. https://lakemedelsverket.se/Alla-nyheter/NYHETER---2018/CBD-produkter-ska-folja-lakemedelslagen/.

latimes.com

articles.latimes.com

Lee Romney (13 september 2012). ”On the frontier of medical pot to treat boy's epilepsy” (på engelska). Los Angeles Times. http://articles.latimes.com/2012/sep/13/local/la-me-customized-marijuana-20120914. Läst 8 juli 2015.

mayoclinicproceedings.org

”Clinicians’ Guide to Cannabidiol and Hemp Oils”. mayoclinicproceedings.org. https://www.mayoclinicproceedings.org/article/S0025-6196(19)30007-2/fulltext. Läst 31 mars 2022.

medscape.com

Wilner, AN (25 mars 2014). ”Marijuana for Epilepsy: Weighing the Evidence” (på engelska). Medscape Neurology. WebMD. http://www.medscape.com/viewarticle/822445_3. Läst 8 juli 2015.

nih.gov

ncbi.nlm.nih.gov

Borgelt LM, Franson KL, Nussbaum AM, Wang GS (februari 2013). ”The pharmacologic and clinical effects of medical cannabis” (på engelska). Pharmacotherapy 33 (2): sid. 195–209. doi:10.1002/phar.1187. PMID 23386598.
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (december 2012). ”Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders” (på engelska). Philosophical Transactions of the Royal Society B: Biological Sciences 367 (1607): sid. 3364–3378. doi:10.1098/rstb.2011.0389. PMID 23108553.
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (August 2007). "Cannabidiol—recent advances". Chem. Biodivers. (Review). 4 (8): 1678–92. doi:10.1002/cbdv.200790147. PMID 17712814.
Pertwee RG (2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin". British Journal of Pharmacology. 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007). "The orphan receptor GPR55 is a novel cannabinoid receptor". British Journal of Pharmacology. 152 (7): 1092–101. doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR (January 2010). "Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors". British Journal of Pharmacology. 159 (1): 122–8. doi:10.1111/j.1476-5381.2009.00521.x. PMC 2823358. PMID 20002102.
Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS (January 2009). "5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats". British Journal of Pharmacology. 156 (1): 181–8. doi:10.1111/j.1476-5381.2008.00046.x. PMC 2697769. PMID 19133999.
Campos AC, Guimarães FS (August 2008). "Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats". Psychopharmacology. 199 (2): 223–30. doi:10.1007/s00213-008-1168-x. PMID 18446323.
Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K, Fujiwara M (May 2005). "Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism". Stroke; a Journal of Cerebral Circulation. 36 (5): 1077–82. doi:10.1161/01.STR.0000163083.59201.34. PMID 15845890
Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX, Fujioka M, Abe K, Hasebe N, Egashira N, Iwasaki K, Fujiwara M (March 2007). "Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance". Neuropharmacology. 52 (4): 1079–87. doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118
Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (2006). "Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 372 (5): 354–361. doi:10.1007/s00210-006-0033-x. PMID 16489449

reuters.com

Lubell, Maayan (3 juli 2012). ”What a drag, Israeli firm grows 'highless' marijuana” (på engelska). Reuters. Arkiverad från originalet den 11 juli 2012. https://wayback.archive-it.org/all/20120711232134/http://www.reuters.com/article/2012/07/03/uk-israel-marijuana-idUSLNE86201S20120703. Läst 8 juli 2015.

thelancet.com

”Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. thelancet.com. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30401-8/fulltext. Läst 31 mars 2022.

web.archive.org

McPartland JM, Russo EB (2001). ”Arkiverade kopian” (på engelska). Journal of Cannabis Therapeutics 1 (3/4): sid. 103–132. doi:10.1300/J175v01n03_08. Arkiverad från originalet den 22 juni 2017. https://web.archive.org/web/20170622203721/http://www.cannabis-med.org/data/pdf/2001-03-04-7.pdf. Läst 8 juli 2015.
Alastair Good (26 oktober 2010). ”Growing marijuana that won't get you high” (på engelska). The Daily Telegraph, London. Arkiverad från originalet den 28 januari 2016. https://web.archive.org/web/20160128082457/http://se.formulaswiss.com/. Läst 8 juli 2015.

wired.com

Olivia Solon (5 juli 2012). ”Medical Marijuana Without the High” (på engelska). Wired.com. http://www.wired.com/wiredscience/2012/07/marijuana-high-arthritis/. Läst 8 juli 2015.